Solid Tumors Clinical Trial
— LE-DTOfficial title:
A Phase 1 Study of Liposome Encapsulated Docetaxel (LE-DT) in Patients With Advanced Solid Tumors
Verified date | June 2011 |
Source | INSYS Therapeutics Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Liposome Encapsulated Docetaxel (LE-DT) is a novel proprietary delivery system of docetaxel developed by NeoPharm, Inc. In this Phase I study, the LE-DT was evaluated for the maximum tolerated dose and dose limiting toxicity (DLT) in patients with advance solid tumors. It was also evaluated for pharmacokinetic and anti-tumor effects.
Status | Completed |
Enrollment | 30 |
Est. completion date | May 2010 |
Est. primary completion date | May 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - To be included in this study, patients must meet the following criteria: - Be =18 years of age. - Have advanced (local and/or metastatic) histologically documented cancer considered unresponsive to available conventional modalities or treatments. - Have an ECOG Performance Status of 0-2. - Have recovered from acute toxicities of prior treatment: - 4 weeks must have elapsed since receiving any investigational agent. - 4 weeks must have elapsed since receiving any radiotherapy, or treatment with cytotoxic or biologic agents (=6 weeks for mitomycin or nitrosoureas). Chronic treatment with non-investigational gonadotropin-releasing hormone analogs or other hormonal or supportive care is permitted. - >6 months must have elapsed since receiving a high-dose chemotherapy regimen with stem cell support. - 2 weeks must have elapsed since any prior surgery or granulocyte-stimulating growth factor therapy. - 12 months must have elapsed since any prior treatment with docetaxel. 5. Be in adequate condition as evidenced by the following clinical laboratory values: - Absolute neutrophil count (ANC) =1,500/mm3. - Platelets =100,000/mm3. - Hemoglobin =9.0 g/dL. - Albumin =3.0 g/dL. - Serum creatinine =2.0 mg/dL. - Total bilirubin =1.5 x institutional upper limit normal (ULN). - Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase =2.5 x ULN. 6. Patients (male and female) must be willing to practice an effective method of birth control during the study. 7. Patient or legal representative must understand the investigational nature of this study and sign an Institutional Review Board (IRB)/Independent Ethics Committee approved written informed consent form prior to treatment. Exclusion Criteria: - Patients are excluded from this study for the following: 1. Active uncontrolled bleeding or bleeding diathesis (e.g., active peptic ulcer disease). 2. Any active infection requiring parenteral or oral antibiotic treatment. 3. Known infection with human immunodeficiency virus or hepatitis virus. 4. Active heart disease including myocardial infarction or congestive heart failure within the previous 6 months, symptomatic coronary artery disease, or arrhythmias currently requiring medication. 5. Known or suspected active central nervous system metastasis. (Patients stable 8 weeks after completion of treatment for central nervous system metastasis are eligible.) 6. Impending or symptomatic spinal cord compression or carcinomatous meningitis. 7. Having pre-existing clinically significant neuropathy (NCI CTCAE Grade = 2 neuromotor or Grade = 2 neurosensory) except for abnormalities due to cancer. 8. Having failed a docetaxel-containing regimen. 9. Having known non-controllable hypersensitivity to docetaxel or liposomes. 10. Currently receiving any other standard or investigational treatment for cancer or any other investigational agent for any indication. 11. Requiring immediate palliative treatment of any kind including surgery and/or radiotherapy. 12. Female patients who are pregnant or breast-feeding. 13. Unwilling or unable to follow protocol requirements. 14. Any condition which, in the Investigator's opinion, deems the patient an unsuitable candidate to receive study drug. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | TGEN/Scottsdale Clinical Research Institute | Scottsdale | Arizona |
United States | Lombardi Comprehensive Cancer Center, Georgetown University | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
INSYS Therapeutics Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the tolerability and safety | This Phase I, open-label, dose-escalation study was designed to determine the maximum tolerated dose (MTD) of LE-DT in patients with advanced cancer. LE-DT was administered by intravenous infusion, over 1 hour, once every 21 days until occurrence of disease progression or toxicity requiring early treatment discontinuation. Dose escalation was not done until the safety and tolerability at a given dose level has been confirmed. | 1 year | Yes |
Secondary | To evaluate the pharmacokinetic and anti-tumor effect | The patients were evaluated for pharmacokinetic profile upto 48 hours post treatment after cycle 1. The anti-tumor effects were evaluated after every two cycles of treatment. | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |